Noninvasive Monitoring of Pulmonary Fibrosis by Targeting Matrix Metalloproteinases (MMPs)

摘要: While idiopathic pulmonary fibrosis (PF) is a devastating lung disease, the management of PF including effective monitoring disease progression remains challenge. Herein, we introduce novel, fast, and ultrasensitive metalloproteinase (MMP) activatable optical probe, named MMP-P12, to noninvasively monitor response treatment. A bleomycin (BLM)-induced mouse model was subjected imaging at various time points after BLM The developed during 21 days experimental period, well correlated with stepwise increase MMP-2 expression as examined by quantitative RT-PCR Western blot analysis on 7-, 14-, 21-day post-BLM administration. On these days, MMP-activated fluorescence images were acquired in vivo ex vivo. Signal quantification showed time-dependent lung-specific incremental increases signals. As treatment for PF, secretoglobin 3A2 daily administered intravenously five starting day seven administration, which resulted reduced activity reduction previously demonstrated. Importantly, signal that reflected MMP also decreased intensity. In conclusion, MMPs may play an important role development MMP-P12 probe could be promising tool detection, even early stage indicator therapy response.